Public Profile

Santarus, Inc.

Santarus, Inc., a prominent biopharmaceutical company headquartered in the United States, has established itself as a leader in the development of innovative therapies for gastrointestinal and rare diseases. Founded in 2003, Santarus has achieved significant milestones, including the successful launch of several FDA-approved products that address unmet medical needs. The company focuses on specialised areas such as inflammatory bowel disease and other gastrointestinal disorders, offering unique formulations that enhance patient compliance and treatment outcomes. Santarus is recognised for its commitment to research and development, positioning itself strongly within the biopharmaceutical industry. With a robust portfolio of core products, Santarus continues to make strides in improving the quality of life for patients worldwide.

DitchCarbon Score

How does Santarus, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

30

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Santarus, Inc.'s score of 30 is higher than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.

54%

Let us know if this data was useful to you

Santarus, Inc.'s reported carbon emissions

Santarus, Inc., headquartered in the US, currently does not have available carbon emissions data for the most recent year, nor do they have documented reduction targets or initiatives. Without specific emissions figures or commitments, it is unclear how the company is addressing its carbon footprint or contributing to climate action. In the absence of concrete data, it is essential for Santarus, Inc. to establish clear climate commitments and reduction strategies to align with industry standards and expectations for sustainability.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Santarus, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Santarus, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Santarus, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Hi-Tech Pharmacal Co., Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 11 days ago

Obagi

US
Pharmaceutical Preparation Manufacturing
Updated 11 days ago

Chiesi USA, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 11 days ago

Jazz Pharmaceuticals

GB
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Sagent Pharmaceuticals, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 11 days ago

Lannett Company, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 11 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers